On Wednesday, Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), inclined 0.67% to $7.53, during its last trading session.
ARIAD Pharmaceuticals declared that the first patient has been treated in its OPTIC (Optimizing Ponatinib Treatment In CML) trial of Iclusig (ponatinib). This randomized, dose-ranging trial is designed to evaluate three starting doses of ponatinib in patients with refractory, chronic-phase chronic myeloid leukemia (CP-CML) and is predictable to inform the optimal use of Iclusig in these patients. About 450 patients will be enrolled at clinical sites around the world.
“Ongoing analyses of dose reductions among patients enrolled in the Phase 1 trial and Phase 2 PACE trial of ponatinib have shown sustained responses among patients whose ponatinib dosages were reduced,” stated Jorge E. Cortes, M.D., Professor and Deputy Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center. “The trial will provide randomized clinical data on the benefit and risk of initiating this treatment at lower doses. It is hoped that it will assist us make treatment decisions for patients with CML who have become resistant to other tyrosine-kinase inhibitors (TKIs).”
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
At the end of Wednesday’s trade, Shares of Integrated Device Technology Inc (NASDAQ:IDTI), gained 1.69% to $19.87.
Integrated Device Technology introduced two new members to its growing family of RF voltage variable attenuators (VVA), expanding IDT’s frequency coverage to a range of 1 MHz to 6 GHz. Like the other members of the family, the F2255 and F2258 devices offer industry-leading low insertion loss and high linearity.
IDT’s VVAs deliver analog control for applications that require precise attenuation. Both new devices come in a compact 3 millimeter by 3 millimeter, 16-pin TQFN package. They offer about half the insertion loss of competitive solutions, IP3 performance 1000x (30 dB) better than the competing Gallium arsenide (GaAs) device, and they exhibit a linear-in-dB attenuation characteristic across the voltage control range. Their low insertion loss reduces RF chain path loss, while their high linearity improves system data rates.
These newest devices match popular footprints and are ideal for base stations (2G, 3G and 4G), microwave infrastructure, public safety, portable wireless communication/data equipment, test/ATE equipment, military systems, JTRS radios, and HF, VHF and UHF radios.
Integrated Device Technology, Inc. designs, develops, manufactures, and markets a range of semiconductor solutions for the communications, computing, and consumer industries worldwide. It operates in two segments, Communications, and Computing and Consumer.
Finally, Zoetis Inc (NYSE:ZTS), ended its last trade with -0.73% loss, and closed at $47.86.
Zoetis Inc., stated its financial results for the second quarter of 2015 and updated its full year 2015 guidance.
The company stated revenue of $1.2 billion for the second quarter of 2015, which raised 1% contrast to the second quarter of 2014. Revenue reflected an operational2 enhance of 11%, not taking into account the impact of foreign exchange.
The net loss for the second quarter of 2015 was $37 million, or $0.07 per diluted share, which comprises $263 million in pre-tax charges related to the company’s formerly declared comprehensive operational efficiency initiative. Adjusted net income1 for the second quarter of 2015 was $216 million, or $0.43 per diluted share, an enhance of 14% and 13%, respectively. Adjusted net income for the second quarter of 2015 excludes the net impact of $253 million, or $0.50 per diluted share, for purchase accounting adjustments, acquisition-related costs and certain noteworthy items. On an operational basis, adjusted net income for the second quarter of 2015 raised 20%, with foreign currency having a negative impact of 6 percentage points.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. The company operates through four segments: the United States; Europe/Africa/Middle East; Canada/Latin America; and Asia/Pacific.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
